Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Two Small Companies See Huge Opportunities In Heart Failure Device Space

CardioKinetix And CircuLite Reach Important Milestones With Their US Clinical Trial Programs

Executive Summary

CardioKinetix, maker of a unique, percutaneously placed ventricular partitioning device, and CircuLite, which is developing a less invasive cardiac assist device, are moving into US clinical trials with their technologies – an important milestone for emerging companies in the difficult heart failure space. Both offer therapies aimed at helping fill the huge heart failure treatment gap that exists today.

Advertisement

Related Content

European Markets Show Pockets Of Strong Growth For Cardiovascular Devices
Tug Of War In The LVAD Market
BioVentrix: Reshaping Heart Failure
Heart Failure Start-Ups Balance High-Risk, High-Reward Opportunity
Pressure Builds In Ventricular Assist Market
Heart Failure Devices: Raising Roadblocks To Readmission

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT035611

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel